Anika Therapeutics, Inc.
ANIK
$15.05
$0.020.13%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1,155.61% | -6.54% | -5.37% | 6.85% | -107.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,155.61% | -6.54% | -5.37% | 6.85% | -107.32% |
| Cost of Revenue | 248.42% | 136.56% | -5.05% | 2.27% | -158.09% |
| Gross Profit | 207.14% | -94.40% | -5.55% | 9.88% | -76.62% |
| SG&A Expenses | 172.65% | -23.02% | -16.39% | -1.74% | -167.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 211.24% | 31.57% | -12.88% | -0.72% | -160.36% |
| Operating Income | -100.40% | -259.75% | 104.43% | 23.60% | 504.69% |
| Income Before Tax | -99.85% | -292.26% | 124.63% | 62.79% | 495.54% |
| Income Tax Expenses | -72.11% | 598.27% | 356.53% | 102.58% | 710.32% |
| Earnings from Continuing Operations | -115.32% | -354.96% | 96.79% | 56.39% | 430.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.29% | -354.96% | 96.79% | 56.39% | -1,183.62% |
| EBIT | -100.40% | -259.75% | 104.43% | 23.60% | 504.69% |
| EBITDA | -92.62% | -571.63% | 2,839.51% | 16.37% | 1,259.80% |
| EPS Basic | 65.11% | -350.90% | 96.84% | 56.52% | -1,182.49% |
| Normalized Basic EPS | -97.44% | -286.04% | 124.35% | 25.31% | 533.20% |
| EPS Diluted | 65.11% | -351.11% | 94.74% | 56.34% | -1,168.11% |
| Normalized Diluted EPS | -97.45% | -286.04% | 124.35% | 25.31% | 533.20% |
| Average Basic Shares Outstanding | -0.54% | 0.91% | 1.03% | 0.31% | 0.11% |
| Average Diluted Shares Outstanding | -0.22% | 0.91% | 1.03% | 0.31% | 0.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
